Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...
Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...
This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...
GlobalData on MSN14d
Alltrna plans to tackle rare diseases using tRNA-based therapiesAlltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
The pioneering research of UC Santa Cruz’s Upasna Sharma to determine how a father’s life experiences and environment can ...
News-Medical.Net on MSN3d
Novel regulators in digestive tract disease progression and treatmentThis new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...
Tyr Pharma (ATYR) announced a publication demonstrating the mechanism of action for its lead therapeutic candidate, efzofitimod, in the ...
Most individuals diagnosed with a rare disease won’t live to become teenagers or adults. I knew what I had to do.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback